Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Baricitinib, an Oral Janus Kinase (JAK) 1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-BEACON Study Genovese, M., Kremer, J., Zamani, O., Ludivico, C., Krogulec, M., Xie, L., Beattie, S., Koch, A., Cardillo, T., Rooney, T., Macias, W., Schlichting, D., Smolen, J., Bookman, A. J RHEUMATOL PUBL CO. 2016: 1188
View details for Web of Science ID 000380879100134